Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer

NCT04220203 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

HER2-positive Breast Cancer

Interventions

DRUG: Tucatinib
DRUG: Capecitabine
DRUG: Trastuzumab

Sponsor

Seagen, a wholly owned subsidiary of Pfizer

Collaborators

[object Object]